BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit
2024年6月19日 - 8:00PM
ビジネスワイヤ(英語)
BenevolentAI ("BenevolentAI" or the "Company") (Euronext
Amsterdam: BAI), a leader in applying advanced AI to accelerate
biopharma drug discovery, today announces that it will participate
in the upcoming Morgan Stanley 3rd Annual Life Sciences AI Summit,
26-27 June 2024, in New York, US.
Dr Joerg Moeller MD, Chief Executive Officer, is scheduled to
take part in the panel discussion ‘Value Creation with AI for Drug
Discovery’ at 09:55 EDT (14:55 BST), 27 June 2024, moderated by
Vikram Purohit, Executive Director & Equity Analyst, Morgan
Stanley.
Dr Moeller and members of the Company’s leadership team will
also be available throughout the conference for meetings on-site
and adjacent to the programme (see contact details below).
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our
proprietary and validated Benevolent Platform™ that integrates AI
and science to uncover new biology, predict novel targets and
develop first-in-class or best-in-class drugs for complex diseases.
By applying proprietary advanced AI tools, in combination with
in-house scientific expertise and wet-lab facilities, BenevolentAI
is well-positioned to identify and accelerate novel drug
discovery.
The Company’s business model presents multiple routes for value
creation including discovery collaborations with pharma companies
like AstraZeneca and Merck and advancing in-house pipelines to
inflection points. Headquartered in London, with wet labs in
Cambridge (UK), BenevolentAI is at the forefront of reshaping the
future of drug discovery and delivering innovative medicines.
Category: non-regulatory
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240619744385/en/
INVESTORS Catherine Isted – Chief Financial Officer
investors@benevolent.ai
MEDIA James Osborn – Communications Lead
press@benevolent.ai
FTI CONSULTING Ben Atwell/Simon Conway/Victoria Foster
Mitchell T: +44 203 727 1000 BenevolentAI@fticonsulting.com